You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

112 Results
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - In Combination with Pembrolizumab for First-Line Advanced or Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lenvatinib,
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
*/
Document
Apr 2025
Document
New
Jun 2025
Document
New
Jun 2025
Document
New
Jun 2025
Document
New
Jul 2025
Document
New
Jul 2025
Document
New
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
amivantamab (Unfunded),
lazertinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Drug
Other Name(s): Vitrakvi®
Quick Link(s): Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Reblozyl®
Quick Link(s): Drug Monograph, Patient Info Sheet
Sep 2025

Pages